Due to MUC1 expression specifically in human OTSCC, the feasibility of MUC1-CAR in CAR-T cell trials, the ready availability, safety profile, and emerging-evidenced efficacy in fighting cancer of CAR-NK cells, we initially developed and tested the iPSC-derived MUC1-targeted CAR-NK cells’ cytotoxicity against MUC1-expressing human OTSCC cells in vitro and in BNDG mouse xenograft models (24–30). The gene discussed is MUC1; the disease is cancer.